Juno Therapeutics Inc. (Nasdaq: JUNO) entered a 10-year, $1 billion collaboration agreement with Celgene Corp. (Nasdaq: CELG). Shares of Juno leaped $9.42 to $55.72 while Celgene stock edged up 3 cents to $114.94.